A blister package is disclosed herein. The blister package includes a body, a plurality of pockets, and a top seal. The body has a top surface and a bottom surface opposite the top surface. The plurality of pockets is formed in the body. Each of the plurality of pockets extend below the top surface of the body. Each pocket of the plurality of pockets is configured to hold a pharmaceutical. The plurality of pockets is arranged in a manner that defines at least one dose. The plurality of pockets for the at least one dose includes a first pocket in parallel with a second pocket, and a third pocket perpendicular to the first pocket and the second pocket. The top seal is configured to interface with the body. The top seal is configured to hold the pharmaceutical in each respective pocket.
A61J 1/03 - Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
B65D 75/36 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages
The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.
This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I) and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination with an additional anti-cancer agent.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Compounds are provided having the following structure: or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, Y, m, n, w and x are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a payload, compositions comprising the compounds and methods for their use and preparation are also provided.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, L, X, Y and p are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may modulate the activity of antigens of interest and may be useful in inducing or enhancing an immune response against diseases, disorders and conditions mediated by antigens of interest.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
C08H 1/00 - Macromolecular products derived from proteins
17.
COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CDK7 INHIBITORS FOR THE TREATMENT OF CANCER
Disclosed herein are methods for treating cancer comprising administering to a subject Compound A, or a pharmaceutically acceptable salt thereof, in combination with a selective CDK7 inhibitor.
SOLID FORMS OF (R)-N-(3-(7-METHYL-1H-INDAZOL-5-YL)-1-(4-(1-METHYLPIPERIDIN-4-YL)PIPERAZIN-1-YL)-1-OXOPROPAN-2-YL)-4-(2-OXO-1,2-DIHYDROQUINOLIN-3-YL)PIPERIDINE-1-CARBOXAMIDE
Disclosed herein is a crystalline form of zavegepant, wherein the crystalline form is a crystalline monohydrochloride acetone solvate. Also disclosed herein is an amorphous form of the hydrochloride salt of zavegepant. Methods of making these solid forms as well as pharmaceutical compositions comprising the same are also disclosed.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
This invention relates to high drug loading formulations comprising solid amorphous dispersions of encorafenib, together with one or more surfactants and polymers, and to methods of using such solid forms and pharmaceutical compositions in the treatment of proliferative diseases such as cancer.
Provided herein are methods of treatment of cancers, specifically multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies in combination with anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
This disclosure relates to a crystalline form of 4-[(1R)-1-aminopropyl]-2-{6-[(5S)-5-methyl-6,7-dihydro-5H-pyrro-lo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin- 1-one (PF-07265028) free base and method of making thereof. The disclosure also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
24.
S)-2-OXOPYRROLIDIN-3-YL]ETHYL}-4-(TRIFLUOROMETHYL)-L-PROLINAMIDE AND SOLVATES THEREOF
The present disclosure is directed to solid forms of N-(Methoxycarbonyl)-3-methyl-L- valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-L- prolinamide, I, such as anhydrous forms thereof, an amorphous form thereof, a cyclopentyl methyl ether solvate thereof, an isopropyl acetate solvate thereof, and an 5 ethyl acetate solvate thereof formula (I) and to pharmaceutical compositions comprising the solid forms and methods of treatment employing the solid forms.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure is directed to processes for preparing N-(Methoxycarbonyl)-3- methyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4- (trifluoromethyl)-L-prolinamide, I, and forms thereof such as the Form I polymorph thereof, a cyclopentyl methyl ether solvate thereof, the isopropyl acetate solvate thereof, the ethyl acetate solvate thereof and a mixture of the Form 1 polymorph thereof and microcrystalline cellulose (I) and to compositions comprising the solid forms and to intermediates used to prepare Compound I.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
The invention relates to dosing regimens for the treatment of RSV infection comprising administering to a pediatric subject in need thereof a daily dose of a sisunatovir as a single agent or in combination with other RSV therapies.
Systems and methods for performing biological assays are provided herein. The systems and methods determine one or more characteristics of a nucleic acid amplification sample based on a modified optical property of the sample.
The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
Embodiments disclosed herein may provide digital medicine support for predicting and mitigating side effects of bispecific antibody treatment (e.g., Pfizer's Elranatamab) for myeloma patients. The side effects may include cytokine release syndrome (CRS), infection (e.g., sepsis), neurotoxicity (e.g., peripheral neuropathy), cytopenia (e.g., neutropenia), etc. These side effects may be predicted based on passive collection of data from patient wearables, patient entered data on healthcare application, and other data such as bloodwork data. Trained machine learning models may be used for predicting the side effects. As the side effects may be predicted before their onsets, a proactive intervention may be feasible to improve the healthcare outcomes for myeloma patients.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
31.
COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CDK4 INHIBITORS
Disclosed herein are methods for treating cancer comprising administering to a subject Compound A, or a pharmaceutically acceptable salt thereof, in combination with a selective CDK4 inhibitor.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
38.
DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES
A digital medicine companion for managing skin diseases (e.g., atopic dermatitis, psoriasis) may include patient wearable devices passively collecting patient data, patient user devices with healthcare applications for the patient to enter health related data, central analytics for flare prediction and disease progress tracking, and a clinician dashboard. For flare prediction, a prediction tool may be trained using the ground truth of recorded flare occurrences for the trained model to predict whether observed scratch events may result in a flare. Upon predicting a likely flare, alert notifications may be generated, e.g., for a clinician and/or the patient. Furthermore, a baseline may be established based on the data passively gathered from the wearables and actively gathered from the patient user devices. The continuously collected data may be compared against the established baseline. Upon detecting a significant deviation, alerts may be sent to the patient and/or the clinician.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure relates to engineered RNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered RNA polymerase polypeptides. The present disclosure also provides methods of using the engineered RNA polymerase polypeptides or compositions thereof for producing RNA.
41.
Modulators of STING (Stimulator of Interferon Genes)
Provided herein are compounds of the general formula (I):
Provided herein are compounds of the general formula (I):
Provided herein are compounds of the general formula (I):
and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
55.
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
09 - Scientific and electric apparatus and instruments
Goods & Services
Downloadable mobile applications for tracking injections for the treatment and prevention of endocrine diseases and disorders; Downloadable software for tracking injections for the treatment and prevention of endocrine diseases and disorders
57.
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF
Described herein are compounds of Formula I:
Described herein are compounds of Formula I:
Described herein are compounds of Formula I:
and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
58.
N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS
The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
The invention is directed to Anti-LILRB1 and anti-LILRB2 bispecific antibodies, anti-LILRB1 antibodies, and anti-LILRB2 antibodies, their uses and pharmaceutical compositions thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
In an embodiment, there is provided a varenicline formulation consisting essentially of about 0.85% varenicline tartrate and greater than 1.75% to about 3.0% propyl gallate, wherein the formulation maintains a level of N-nitrosovarenicline (NNV) impurity over the shelf-life of the formulation of not more than 18.5 ppm (37 ng/day) of acceptable daily intake (ADI). In another embodiment, there is provided a varenicline formulation comprising a tablet core comprising about 0.85% varenicline tartrate, about 60.50% microcrystalline cellulose, about 33.33% dibasic calcium phosphate anhydrous, about 2.00% croscarmellose sodium, about 2.57% propyl gallate, and about 0.75% magnesium stearate; and a film coating.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Cells having improved growth and related cell cultures are provided. In some aspects, cells provided herein have increased expression of thioredoxin interacting protein (TXNIP).
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
67.
METHODS OF TREATING HEPATIC-ONLY METASTATIC UVEAL MELANOMA
Provided herein is a method of treating metastatic uveal melanoma (MUM) in a patient having a hepatic tumor and an essential absence of an extra-hepatic tumor with a PKC inhibitor and a c-MET inhibitor.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
68.
LILRB1 AND LILRB2 ANTIBODIES AND METHODS OF USE THEREOF
The invention is directed to Anti-LILRB1 and anti-LILRB2 bispecific antibodies, anti-LILRB1 antibodies, and anti-LILRB2 antibodies, their uses and pharmaceutical compositions thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their Intermediate; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
76.
IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
78.
NOVEL 5-CYCLOPROYLQUINOLINE DERIVATIVES AS PLPRO INHIBITORS
The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1to R3 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity and/or expression of PLpro and may be useful in the treatment, prevention, suppression, and amelioration of viral infections characterized with PLpro activity and/or expression such as coronavirus infections.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for treatment of dermatomyositis and lupus
80.
COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A C-MET INHIBITOR
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
The invention relates to substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5'-monophosphate- activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.
The disclosure relates to a method for activating a medical testing device via near-field communication. The method can include verifying a digitally signed message received from a user device using a public key in a medical testing device. The medical testing device can be activated after the verification of the digitally signed message.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The invention relates to a method of forming multi-specific antibodies from first and second homodimer antibodies comprising the steps of: - providing at least one solution including the homodimer antibodies; - loading said at least one solution onto an adsorbent chromatography medium, whereby the homodimer antibodies bind to the medium; - contacting the bound antibodies with a reductant; and - eluting the bound antibodies with an elution buffer thereby obtaining an eluate pool. The method further comprises, after the step of contacting the bound antibodies with a reductant, a step of contacting the bound or eluted antibodies with an oxidant, whereby multi-specific antibodies are formed from first and second homodimer antibodies. The invention is also directed to a pharmaceutical product including multi-specific antibodies obtained by such a method.
This invention relates to a method of selecting a subject having a cancer for treatment, comprising: i) determining a KAT6A level from a biological sample of the cancer from the subject; ii) selecting the subject for treatment and iii) administering to the selected subject an amount of with one of: a) a lysine acetyltransferase 6A (KAT6A) inhibitor; b) a lysine acetyltransferase 6A (KAT6A) inhibitor and a cyclin-dependent kinase 4 (CDK4) inhibitor; c) a lysine acetyltransferase 6A (KAT6A) inhibitor and an antiestrogen; and d) a lysine acetyltransferase 6A (KAT6A) inhibitor, a cyclin-dependent kinase 4 (CDK4) inhibitor, and an antiestrogen, based on the KAT6A level, wherein the KAT6A level is determined to be high.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
88.
KAT6A AS A PREDICTIVE BIOMARKER FOR TREATMENT OF BREAST CANCER WITH A CDK4 INHIBITOR AND AN ANTIESTROGEN AND METHODS OF TREATMENT THEREOF
This invention relates to a method of selecting a subject having a cancer for treatment, comprising: i) determining a KAT6A level from a biological sample of the cancer from the subject; ii) selecting the subject for treatment with a cyclin-dependent kinase 4 (CDK4) inhibitor as a single agent or in combination with an antiestrogen, based on the KAT6A level, wherein the KAT6A level is determined to be low, and methods of treatment thereof. It is shown that lower than median KAT6A mRNA levels in metastatic tumor samples of patients with breast cancer qualify as a predictive biomarker for the response to a combination therapy with palbociclib and fulvestrant.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof. In one embodiment, the compositions comprise a polypeptide derived from E. coli or a fragment thereof, and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides or conjugates thereof. In a further aspect, the compositions further comprise modified O-polysaccharide molecules derived from Klebsiella pneumoniae or conjugates thereof.
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
Vectors and nucleic acid constructs for improved antibody production are provided. Also provided are methods of making and using the vectors and constructs.
S. pneumoniaeS. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;
The present disclosure provides methods and compositions for modulating the innate immunity to exogenous ribonucleic acid (RNA) when administered to a subject in need thereof. More particularly, the disclosure provides compositions comprising RNA encoding at least one antigen or therapeutic protein, and at least one compound that modulates the innate immunity to such RNA when administered to a subject in need thereof. The disclosure further provides methods of using such compounds to modulate the innate immunity of such compositions.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Methods for producing a compound of Formula I, Formula I, wherein R1 and R2 are independently a i) linear or branched or cyclic, ii) saturated or unsaturated, and iii) substituted or unsubstituted hydrocarbon group comprising 8 to 20 carbon atoms; R3 is a hydrocarbon group; n is an integer from 2 to 5, m is an integer from 30 to 70, and L is a linker. The method includes: a) contacting a fatty acid having a chemical formula of R1—COOH and a primary amine having a chemical formula of R2—NH2 to form an amide having a chemical formula of R1—C(O)—NH—R2; b) contacting the amide with a reducing agent to form a secondary amine having a chemical formula of R1—CH2—NH—R2; and c) contacting the secondary amine with a polyolefin-glycol compound to form the compound of Formula I. Intermediates produced in the method, salts of compound of Formula I and of intermediates.
Methods for producing a compound of Formula I, Formula I, wherein R1 and R2 are independently a i) linear or branched or cyclic, ii) saturated or unsaturated, and iii) substituted or unsubstituted hydrocarbon group comprising 8 to 20 carbon atoms; R3 is a hydrocarbon group; n is an integer from 2 to 5, m is an integer from 30 to 70, and L is a linker. The method includes: a) contacting a fatty acid having a chemical formula of R1—COOH and a primary amine having a chemical formula of R2—NH2 to form an amide having a chemical formula of R1—C(O)—NH—R2; b) contacting the amide with a reducing agent to form a secondary amine having a chemical formula of R1—CH2—NH—R2; and c) contacting the secondary amine with a polyolefin-glycol compound to form the compound of Formula I. Intermediates produced in the method, salts of compound of Formula I and of intermediates.
C08G 69/40 - Polyamides containing oxygen in the form of ether groups
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention provides compositions comprising a recombinant AAV (rAAV) vector and one or more pharmaceutically acceptable excipients. The compositions have improved stability as compared to other rAAV compositions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
